Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines for human diseases. The company's mission is to pioneer treatments that transform patients' lives, leveraging a unique approach to gene science. Headquartered in The Woodlands, Texas, Lexicon focuses on translating genetic insights into targeted therapies.

Lexicon utilizes its proprietary genome biology platform and gene knockout technology to identify and advance therapeutic targets. Its diverse pipeline addresses significant unmet medical needs across various therapeutic areas, including cardiometabolic diseases such as diabetes, heart failure, and obesity, as well as neuropathic pain and rare genetic disorders. Key drug candidates include sotagliflozin, marketed as INPEFA for heart failure and previously as ZYNQUISTA for type 1 diabetes, pilavapadin for diabetic peripheral neuropathic pain, and LX9851 for obesity.

In July 2024, Michael Exton was appointed as the new Chief Executive Officer. The company continues to advance its late-stage pipeline, with the pivotal SONATA-HCM Phase 3 study of sotagliflozin for hypertrophic cardiomyopathy targeting enrollment completion in mid-2026 and a potential 2026 resubmission for ZYNQUISTA in type 1 diabetes. Lexicon also initiated a Phase 1 study with Novo Nordisk for the oral obesity drug candidate LX9851 in March 2026. The company is scheduled to report its first-quarter 2026 financial results on May 7, 2026.